[Form 4] CryoPort, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 shows Sangamo Therapeutics (SGMO) CFO Prathyusha Duraibabu surrendered 31,866 common shares on 22-Jul-2025 at $0.4798 per share. The “F” code indicates the shares were withheld by the company to cover taxes triggered by a restricted-stock-unit (RSU) vesting event, not an open-market sale.

After the transaction, the executive still owns 746,279 shares directly. The footnotes detail remaining unvested equity: 178,125 RSU shares from the Jan-2024 grant, 15,030 from Feb-2023, and 120,000 from Feb-2025, all vesting through 2028 if continuous service is maintained. The filing is routine and does not signal a change in outlook or insider sentiment.

Insights

Senior Equity Analyst

TL;DR: Routine tax-withholding share surrender; negligible financial impact.

The CFO’s 31,866-share disposition is compulsory for tax withholding on RSU vesting, worth roughly $15k—immaterial to SGMO’s float. Post-transaction ownership of 746k shares demonstrates continued insider alignment. No purchase or discretionary sale occurred, so the filing is operationally neutral. Investors can view it as routine equity-compensation housekeeping rather than a signal about future fundamentals.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Mandalam Ramkumar

(Last) (First) (Middle)

C/O CRYOPORT INC.

112 WESTWOOD PLACE, SUITE 350

(Street)

BRENTWOOD TN 37027

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cryoport, Inc. [ CYRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/22/2025		M		60,000(1)	A	$3.07	133,056	D
Common Stock	07/22/2025		S		40,728(1)	D	$7.2407(2)	92,328	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.07	07/22/2025		M			60,000(1)	(3)	08/20/2025	Common Stock	60,000	$0.00	0	D

Explanation of Responses:

1. This transaction occurred automatically pursuant to a trading plan adopted by the reporting person on June 10, 2025. The proceeds of the sale of Common Stock were used to pay the exercise price and withholding taxes due upon exercise of the Stock Option reported in this Form 4.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.75 to $7.49, inclusive.

3. 1/48 of the options vested on the 19th of each month for forty-eight months beginning on 8/19/2015.

Remarks:

With respect to prices reported as weighted average prices in Table I, the reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the applicable footnotes to this Form 4.

	/s/ Ramkumar Mandalam	07/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.